What is "canagliflozin"

n. An experimental drug being developed for the treatment of type 2 diabetes.

Canagliflozin ( INN, trade name Invokana or Sulisent) is a drug of the gliflozin class or subtype 2 sodium-glucose transport (SGLT-2) inhibitors used for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson.